[{"orgOrder":0,"company":"Insmed","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Insmed","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"The University of Dundee","sponsor":"Insmed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Dundee","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Dundee \/ Insmed","highestDevelopmentStatusID":"1","companyTruncated":"The University of Dundee \/ Insmed"}]

Find Clinical Drug Pipeline Developments & Deals for Brensocatib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 24, 2025

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 10, 2024

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 30, 2024

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Goldman Sachs & Co

                          Deal Size : $650.0 million

                          Deal Type : Public Offering

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 28, 2024

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Goldman Sachs & Co

                          Deal Size : $500.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 28, 2024

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : INS1007 (brensocatib) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases.

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 31, 2023

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : FDA has granted breakthrough therapy designation to brensocatib for treating patients with NCFBE, recognizing the strength of data from Company's Phase 2 WILLOW study and the potential for brensocatib to offer a novel, first-in-class treatment approach t...

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2020

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : New data from the Phase 2 WILLOW study of brensocatib (formerly known as INS1007) in non-cystic fibrosis bronchiectasis (NCFBE) will be presented during a virtual clinical trials session hosted by the American Thoracic Society (ATS).

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 20, 2020

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The University of Dundee

                          Country arrow
                          Interphex
                          Not Confirmed

                          The University of Dundee

                          Country arrow
                          Interphex
                          Not Confirmed

                          Details : Insmed will provide funding and clinical drug supply for the STOP-COVID19 trial led by the University of Dundee.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 24, 2020

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Insmed

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo.

                          Product Name : INS1007

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 02, 2020

                          Lead Product(s) : Brensocatib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank